Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Alnylam Pharmaceuticals / Equity Bottom-Up

<ul>
<li>This is our first report on biopharma player, Alnylam Pharmaceuticals that is focused on developing novel therapeutics based on the ribonucleic acid interference.</li>
<li>The company has made great progress to bring its commercial RNAi Therapeutics to patients all over the world and advanced its clinical pipelines over various potential transformative programs.</li>
<li>Alnylam Pharmaceuticals recently announced the approval of the RNAi therapeutic, Amvuttra(vutrisiran) administered through subcutaneous injection quarterly.</li>
</ul>


This is our first report on biopharma player, Alnylam Pharmaceuticals that is focused on developing novel therapeutics based on the ribonucleic acid interference.
The company has made great progress to bring its commercial RNAi Therapeutics to patients all over the world and advanced its clinical pipelines over various potential transformative programs.
Alnylam Pharmaceuticals recently announced the approval of the RNAi therapeutic, Amvuttra(vutrisiran) administered through subcutaneous injection quarterly.


Alnylam Pharmaceuticals: Initiation of Coverage – Major Developments

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical (3692 HK)</a> is increasingly focusing on innovative drug, with revenue from such drugs contributing 42% of total revenue in 2021. R&amp;D accounted for 18% of revenue in 2021.</li>
<li>Thus far, in this year, Hansoh received approval for one more new rare-disease drug. Its rich pipeline has 25+ clinical programs of innovative drugs.</li>
<li>With its proven execution on innovative portfolio, sound financial positions, and recent business collaboration effort to enrich the pipeline, Hansoh seems to be an undervalued business.</li>
</ul>



Hansoh Pharmaceutical (3692 HK) is increasingly focusing on innovative drug, with revenue from such drugs contributing 42% of total revenue in 2021. R&amp;D accounted for 18% of revenue in 2021.
Thus far, in this year, Hansoh received approval for one more new rare-disease drug. Its rich pipeline has 25+ clinical programs of innovative drugs.
With its proven execution on innovative portfolio, sound financial positions, and recent business collaboration effort to enrich the pipeline, Hansoh seems to be an undervalued business.


Hansoh Pharmaceutical (3692 HK): Bottom-Fishing Idea; Market Is Overlooking Innovative Portfolio

<ul>
<li>
<a href="https://www.smartkarma.com/entities/bioneer-corp" target="_blank" data-smartkarma-citation="entities:11487:1" rel="noopener">Bioneer Corp (064550 KS) </a>is the only Korean biotech company that provides a total solution for molecular diagnostic, including raw materials, test equipment, and kits. Its molecular diagnostic business is a source of stable cash flow, while its probiotic business is on a high growth trajectory. The company’s new drug pipeline has enabled business expansion in treatment area.</li>
<li>As importance of early prevention and diagnosis is growing with the easing of social distancing, travel, and other restrictions, Bioneer is developing and supplying molecular diagnostic kits and equipment used for diagnosis of various diseases, including COVID as well as product development for life science research. Bioneer is expanding production capacity by 8x and preparing to secure large-scale supply contracts in domestic and international markets.</li>
<li>Through a well-diversified and comprehensive business model, Bioneer aims to become a global bio-health company, with a presence in diagnosis, treatment, and prevention of diseases based on the original technology in the genetic field. This insight has mainly analyzed the strength of each of the business line with and beyond COVID.   </li>
</ul>



Bioneer Corp (064550 KS) is the only Korean biotech company that provides a total solution for molecular diagnostic, including raw materials, test equipment, and kits. Its molecular diagnostic business is a source of stable cash flow, while its probiotic business is on a high growth trajectory. The company’s new drug pipeline has enabled business expansion in treatment area.
As importance of early prevention and diagnosis is growing with the easing of social distancing, travel, and other restrictions, Bioneer is developing and supplying molecular diagnostic kits and equipment used for diagnosis of various diseases, including COVID as well as product development for life science research. Bioneer is expanding production capacity by 8x and preparing to secure large-scale supply contracts in domestic and international markets.
Through a well-diversified and comprehensive business model, Bioneer aims to become a global bio-health company, with a presence in diagnosis, treatment, and prevention of diseases based on the original technology in the genetic field. This insight has mainly analyzed the strength of each of the business line with and beyond COVID.   


Bioneer Corp (064550 KS): Gaining Strength ‘With COVID’ and ‘Beyond COVID’; Poised to Rebound

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

<a href="https://www.smartkarma.com/entities/4489" target="_blank" data-smartkarma-citation="entities:4489:1">Chugai Pharmaceutical (4519 JP)</a> announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi) on Priority Review for adults, adolescents and children with haemophilia A with Factor VIII inhibitors, resulting in a PDUFA date of 23rd February 2018. The announcement was made with one hour of trading left and, if anything, the shares weakened on the news, which underscores that there was little by way of surprise here. The 79% effectiveness and…

Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi) on Priority Review for adults, adolescents and children with haemophilia A with Factor VIII inhibitors, resulting in a PDUFA date of 23rd February 2018. The announcement was made with one hour of trading left and, if anything, the shares weakened on the news, which underscores that there was little by way of surprise here. The 79% effectiveness and…

Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Our next long position is <a href="https://www.smartkarma.com/entities/23721" target="_blank" data-smartkarma-citation="entities:23721:1">Voyager Therapeutics Inc (VYGR US)</a> , a Cambridge, Massachusetts-based emerging biotechnology company that is developing gene therapies for Parkinson's disease (PD) and some other orphan diseases (<a href="http://voyagertherapeutics.com/programs.php" target="_blank">product pipeline</a>). Using its adenovirus vector-based (AAV) gene therapy, the company is targeting about 100,000 PD patients in the US whose motor symptoms are not adequately controlled despite multiple medications. The PD market is about $2.8 billion in size. The company is…

Our next long position is Voyager Therapeutics Inc (VYGR US) , a Cambridge, Massachusetts-based emerging biotechnology company that is developing gene therapies for Parkinson's disease (PD) and some other orphan diseases (product pipeline). Using its adenovirus vector-based (AAV) gene therapy, the company is targeting about 100,000 PD patients in the US whose motor symptoms are not adequately controlled despite multiple medications. The PD market is about $2.8 billion in size. The company is…

New Long Position: Gene Therapy for Parkinson's Disease and Upcoming Catalysts

United States

Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alnylam Pharmaceuticals (ALNY US)

Alnylam Pharmaceuticals: Initiation of Coverage – Major Developments

This is our first report on biopharma player, Alnylam Pharmaceuticals that is focused on developing novel therapeutics based on the ribonucleic...

Baptista Research

Hansoh Pharmaceutical (3692 HK): Bottom-Fishing Idea; Market Is Overlooking Innovative Portfolio

Hansoh has now six innovative drugs in its portfolio. With 40%+ revenue coming from new drugs, Hansoh has best-in-class margin profile. Rich...

Tina Banerjee

Bioneer Corp (064550 KS): Gaining Strength ‘With COVID’ and ‘Beyond COVID’; Poised to Rebound

This insight has mainly analyzed growth prospect of Bioneer's main business of molecular diagnostic beyond COVID-19. Its probiotic business has...

Tina Banerjee

Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data

Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...

Pelham Smithers Associates

New Long Position: Gene Therapy for Parkinson's Disease and Upcoming Catalysts

Our next long position is Voyager Therapeutics Inc (VYGR US) , a Cambridge, Massachusetts-based emerging biotechnology company that is developing...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)